Company Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio, Inc.

Country	United States
Founded	2014
IPO Date	Oct 3, 2019
Industry	Biotechnology
Sector	Healthcare
Employees	101
CEO	Ram Aiyar MBA, Ph.D.

Contact Details

Address: One Kendall Square. Building 600-700, Suite 6-401 Cambridge, Massachusetts 02139 United States
Phone	617-468-1900
Website	korrobio.com

Stock Details

Ticker Symbol	KRRO
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$14.00
CIK Code	0001703647
ISIN Number	US5009461089
Employer ID	47-2324450
SIC Code	2834

Key Executives

Name	Position
Nessan Bermingham Ph.D.	Co-Founder and Executive Chairman
Ram Aiyar MBA, Ph.D.	Chief Executive Officer, President and Director
Dr. Jean-Francois Formela M.D., MBA	Co-Founder and Director
Vineet Agarwal M.B.A.	Chief Financial Officer
Dr. Steven L. Colletti Ph.D.	Chief Scientific Officer
Andrew Fraley Ph.D.	Co-Founder and Chief Technology Officer
Josh Rosenthal Ph.D.	Co-Founder and Advisor
Todd Chappell	Chief Operating Officer
Shelby Walker J.D.	Senior Vice President and General Counsel
Ravi Ramadas Ph.D.	Vice President of Business and Corporate Development

Latest SEC Filings

Date	Type	Title
Apr 18, 2024	424B3	Prospectus
Apr 18, 2024	8-K	Current Report
Mar 28, 2024	424B3	Prospectus
Mar 27, 2024	EFFECT	Notice of Effectiveness
Mar 26, 2024	POS AM	Post-Effective amendments for registration statement
Mar 26, 2024	S-8	Securities to be offered to employees in employee benefit plans
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings